1-tert-Butyl-3-cyano-azetidin | 17358-74-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1-tert-Butyl-3-cyano-azetidin
• 英文别名: 1-tert-Butyl-3-cyan-azetidin；1-(tert-Butyl)azetidine-3-carbonitrile；1-tert-butylazetidine-3-carbonitrile
• CAS: 17358-74-6
• 化学式: C₈H₁₄N₂
• 分子量: 138.213
• InChiKey: FIBARACFLPVZSO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  27
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• HETEROCYCLYLAMINES AS PI3K INHIBITORS
  申请人：Li Yun-Long

  公开号：US20130059835A1

  公开（公告）日：2013-03-07

  The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.

  本发明提供了式I的杂环胺衍生物： 其中变量如本文所定义，调节磷脂酰肌醇3-激酶（PI3Ks）的活性，并且在治疗与PI3Ks活性相关的疾病方面具有用处，例如炎症性疾病、免疫性疾病、癌症和其他疾病。
• PYRIMIDINE COMPOUNDS AS JAK KINASE INHIBITORS
  申请人：THERAVANCE BIOPHARMA R&D IP, LLC

  公开号：US20170312280A1

  公开（公告）日：2017-11-02

  The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of JAK kinases. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.

  该发明提供了式（I）的化合物：其中变量在规范中定义，或其药用盐，这些化合物是JAK激酶的抑制剂。该发明还提供了包含这些化合物的药物组合物，使用这些化合物治疗胃肠道和其他炎症性疾病的方法，以及用于制备这些化合物的过程和中间体。
• ANDROGEN RECEPTOR ANTAGONISTS AND USES THEREOF
  申请人：Tong Youzhi

  公开号：US20140066425A1

  公开（公告）日：2014-03-06

  Disclosed are substituted thioimidazolidinone compounds and pharmaceutical compositions comprising such compounds. The compounds and compositions can be used for treatment of androgen receptor-associated diseases or disorders, such as prostate cancer, benign prostatic hypertrophy, male hair loss and hypertrichosis.

  本发明涉及替代噻唑烷酮化合物和包含这些化合物的药物组合物。这些化合物和组合物可用于治疗与雄激素受体相关的疾病或疾病，例如前列腺癌、良性前列腺增生、男性脱发和多毛症。
• 1,3-DIARYL-SUBSTITUTED HETEROCYCLIC PESTICIDES
  申请人：E I DU PONT DE NEMOURS AND COMPANY

  公开号：US20150126364A1

  公开（公告）日：2015-05-07

  Disclosed are compounds of Formula 1, N-oxides, and salts thereof, wherein Q is and Z 1 , Z 2 , J 1 , J 2 , M, R 1a , R 1b , R 2a , R 2b , R 2c , R 2d , R 14 and R 14a are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound or a composition of the invention.

  本发明揭示了公式1，N-氧化物及其盐的化合物，其中Q为，Z1，Z2，J1，J2，M，R1a，R1b，R2a，R2b，R2c，R2d，R14和R14a如所述的定义。本发明还揭示了包含公式1化合物的组合物以及用于控制无脊椎动物害虫的方法，包括将该害虫或其环境与本发明化合物或组合物的生物有效量接触。
• PYRROLONE OR PYRROLIDINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS
  申请人：Bristol-Myers Squibb Company

  公开号：US20150218092A1

  公开（公告）日：2015-08-06

  The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are melanin concentrating hormone receptor-1 (MCHR1) antagonists which may be used as medicaments.

  本发明提供了公式（I）的化合物：如规范中所定义的和包含任何这种新型化合物的组合物。这些化合物是黑色素浓集激素受体-1（MCHR1）拮抗剂，可以用作药物。